Barclays
XFOR icon

Barclays’s X4 Pharmaceuticals XFOR Stock Holding History

Barclays’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.6K Sell
2,814
-54,686
-95% -$205K ﹤0.01% 4675
2025
Q4 		$230K Buy
+57,500
New +$209K ﹤0.01% 4244
2025
Q2 		– Sell
-6,169
Closed -$43.8K – 5584
2025
Q1 		$43.8K Sell
6,169
-2,703
-30% -$37.2K ﹤0.01% 4649
2024
Q4 		$195K Sell
8,872
-384
-4% -$6.12K ﹤0.01% 4326
2024
Q3 		$186K Buy
9,256
+6,129
+196% +$128K ﹤0.01% 4339
2024
Q2 		$54.4K Sell
3,127
-11,830
-79% -$387K ﹤0.01% 4175
2024
Q1 		$624K Sell
14,957
-2,696
-15% -$75K ﹤0.01% 3457
2023
Q4 		$444K Buy
17,653
+4,915
+39% +$120K ﹤0.01% 3956
2023
Q3 		$417K Buy
12,738
+9,809
+335% +$428K ﹤0.01% 2912
2023
Q2 		$170K Buy
+2,929
New +$151K ﹤0.01% 3322
2022
Q3 		– Sell
-3
Closed – – 5178
2022
Q2 		$0 Sell
3
-257
-99% -$9.78K ﹤0.01% 5298
2022
Q1 		$14K Hold
260
– – ﹤0.01% 4537
2021
Q4 		$18K Sell
260
-70
-21% -$8.86K ﹤0.01% 3956
2021
Q3 		$52K Sell
330
-217
-40% -$35.7K ﹤0.01% 4100
2021
Q2 		$107K Sell
547
-161
-23% -$40.5K ﹤0.01% 3822
2021
Q1 		$183K Buy
708
+275
+64% +$72.3K ﹤0.01% 3743
2020
Q4 		$83K Buy
+433
New +$85.1K ﹤0.01% 4209
2020
Q3 		– Sell
-5
Closed -$1K – 5631
2020
Q2 		$1K Buy
+5
New +$1.37K ﹤0.01% 5476
2020
Q1 		– Sell
-585
Closed -$188K – 6504
2019
Q4 		$188K Buy
585
+390
+200% +$140K ﹤0.01% 5078
2019
Q3 		$74K Buy
+195
New +$77.2K ﹤0.01% 5701
2019
Q2 		– Sell
-8
Closed -$4K – 7327
2019
Q1 		$4K Buy
+8
New +$4.42K ﹤0.01% 6767
2018
Q4 		– Sell
-11
Closed -$3K – 7391
2018
Q3 		$3K Buy
11
+6
+120% +$2.54K ﹤0.01% 6913
2018
Q2 		$3K Hold
5
– – ﹤0.01% 6800
2018
Q1 		$22K Buy
+5
New +$14.5K ﹤0.01% 6397

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Barclays's XFOR Position: Q1 2026 in Review

Barclays reduced its X4 Pharmaceuticals (XFOR) stake by 95% in Q1 2026, selling an estimated $205K and leaving 2,814 shares worth $11.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4675.

Barclays first reported a position in XFOR in Q1 2018 and has held it in 24 quarters since. The position peaked at $624K in Q1 2024. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • Barclays held 2,814 shares of X4 Pharmaceuticals worth $11.6K as of Q1 2026.
  • Barclays sold 54,686 X4 Pharmaceuticals shares in Q1 2026, an estimated $205K.
  • X4 Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4675 holding.
  • Barclays first reported a position in X4 Pharmaceuticals in Q1 2018 and has held it in 24 quarters since.
  • Barclays's X4 Pharmaceuticals position peaked at $624K in Q1 2024.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.